Clinical Trial Update: Canadian Medical Assessment of JINARC™ Outcomes Registry

View source ↗

Summary

Completed Canadian medical assessment of the JINARC outcomes registry for autosomal Dominant Polycystic Kidney Disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• JINARC (tolvaptan)

Snippet

Sponsor: Otsuka Canada Pharmaceutical Inc. | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Status: COMPLETED